C9orf72 hexanucleotide repeat expansions in Chinese sporadic amyotrophic lateral sclerosis by He, Ji et al.
Accepted Manuscript
C9orf72Hexanucleotide Repeat Expansions In Chinese Sporadic Amyotrophic Lateral
Sclerosis
Ji He, Lu Tang, Beben Benyaminx, Sonia Shah, Gib Hemani, Rong Liu, Shan Ye,
Xiaolu Liu, Yan Ma, Huagang Zhang, Katie Cremin, Paul Leo, Naomi R. Wray,
Peter M. Visscher, Huji Xu, Matthew A. Brown, Perry F. Bartlett, Marie Mangelsdorf,
Dongsheng Fan
PII: S0197-4580(15)00313-9
DOI: 10.1016/j.neurobiolaging.2015.06.002
Reference: NBA 9289
To appear in: Neurobiology of Aging
Received Date: 16 December 2014
Revised Date: 5 May 2015
Accepted Date: 1 June 2015
Please cite this article as: He, J., Tang, L., Benyaminx, B., Shah, S., Hemani, G., Liu, R., Ye, S., Liu, X.,
Ma, Y., Zhang, H., Cremin, K., Leo, P., Wray, N.R., Visscher, P.M., Xu, H., Brown, M.A., Bartlett, P.F.,
Mangelsdorf, M., Fan, D., C9orf72Hexanucleotide Repeat Expansions In Chinese Sporadic Amyotrophic
Lateral Sclerosis, Neurobiology of Aging (2015), doi: 10.1016/j.neurobiolaging.2015.06.002.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
He 
 
 
1
TITLE:  
C9orf72Hexanucleotide Repeat Expansions In Chinese Sporadic Amyotrophic 
Lateral Sclerosis 
 
Ji He,*,§,†,2 Lu Tang,*,2 Beben Benyamin,§ Sonia Shah,§ GibHemani,§,† Rong Liu,* 
Shan Ye,* Xiaolu Liu,* Yan Ma,* Huagang Zhang,* Katie Cremin,† Paul Leo,† Naomi 
R. Wray,§ Peter M.Visscher,§,† HujiXu, ‡, Matthew A. Brown,† Perry F. Bartlett,§ 
Marie Mangelsdorf§ and Dongsheng Fan*,1 
 
2Contributed equally in the article 
*Department of Neurology, Peking University Third Hospital, Beijing, China 
§Queensland Brain Institute, University of Queensland, St Lucia, Queensland, 
Australia, 4072 
†University of Queensland Diamantina Institute, Translational Research Institute, 
Woolloongabba, Queensland, Australia, 4102 
‡Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, 
Second Military Medical University, Shanghai, China 
1Corresponding author: Dongsheng Fan 
Address: 49 North Garden Road, Haidian District, Beijing 100191, China 
Phone:  + 86 10 82266699 
Fax:  + 86 10 62017700 
Email:  dsfan2010@aliyun.com 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT He 
 
 
2
ABSTRACT 
A hexanucleotide repeat expansion (HRE) in the C9orf72 gene has been identified 
as the most common mutation in amyotrophic lateral sclerosis (ALS) among 
Caucasian populations. We sought to comprehensively evaluate genetic and 
epigenetic variants of C9orf72 and the contribution of the HRE in Chinese ALS 
cases. We performed fragment-length and repeat-primed PCR to determine 
GGGGCC copy number and expansion within the C9orf72gene in 1,092 sporadic 
ALS (sALS) and 1,062 controls from China. We performed haplotype analysis of 23 
SNPs within and surrounding C9orf72. The C9orf72 HRE was found in three sALS 
patients (0.3%) but not in control subjects (p = 0.25). For two of the cases with the 
HRE, genotypes of 8 SNPs flanking the HRE were inconsistent with the haplotype 
reported to be strongly associated with ALS in Caucasian populations. For these two 
individuals we found hypermethylation of the CpGisland upstream of the repeat, an 
observation not detected in other sALS patients (p< 10-8) or controls. The detailed 
analysis of theC9orf72 locus in a large cohort of Chinese samples provides robust 
evidence that may not be consistent with a single Caucasian founder event. Both the 
Caucasian and Chinese haplotypes associated with HRE were highly associated with 
repeat lengths greater than 8 repeats implying that both haplotypes may confer 
instability of repeat length. 
Keywords: amyotrophic lateral sclerosis; C9orf72 gene; hexanucleotide repeat 
expansion; CpG methylation; Chinese population
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INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder 
characterized by loss of upper and lower motor neurons. The disorder occurs as 
sporadic ALS (sALS) in most cases, while 5-10% of cases are familial (fALS).  
Since SOD1 mutations were linked to fALS in 1993 (Rosen, et al., 1993), a number 
of causative genes have been identified. A large hexanucleotide (GGGGCC) repeat 
expansion (HRE) in the first intron of the C9orf72 gene has been identified as the 
most common mutation detected in ALS and frontotemporal dementia (FTD) 
patients in Caucasian populations (DeJesus-Hernandez, et al., 2011,Millecamps, et 
al., 2012,Renton, et al., 2011). Mutations in these genes may also be found in 
sporadic ALS, but other thanC9orf72HRE each accounts for less than 1% of cases 
(Renton, et al., 2014). 
The C9orf72HRE mutation has been comprehensively screened and assessed in 
Caucasian populations. The HRE frequency amongst sALS cases ranges from 3.2%-
21% in different populations (Beck, et al., 2013,Galimberti, et al., 2014,Majounie, et 
al., 2012,Ratti, et al., 2012,Renton, et al., 2011). However in Asian sALS, it was 
found to be rare in Japanese cohorts (Ishiura, et al., 2012,Konno, et al., 
2012,Majounie, et al., 2012,Ogaki, et al., 2012) and absent in cases from mainland 
China (Jiao, et al., 2014,Liu, et al., 2013,Majounie, et al., 2012,Zou, et al., 2013). 
Additionally, genotypes consistent with a common founder risk haplotype have been 
reported in most C9orf72 HRE-carrying ALS cases in diverse populations, and it has 
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been proposed that the HRE arose in a single common founder ~1,500 years ago 
(Majounie, et al., 2012).  
The function of the protein encoded by C9orf72 remains unclear, however there are 
several hypotheses about functional consequences of the HRE including toxicity of 
the transcribed repeat, toxicity of protein dipeptides translated from the transcribed 
repeat, or loss of function (DeJesus-Hernandez, et al., 2011,Donnelly, et al., 
2013,Gijselinck, et al., 2012,Mori, et al., 2013). Abnormal methylation of the 
CpGisland upstream of the repeat was found in 73% of HRE carriers and was 
associated with downregulation of C9orf72 transcripts (Xi, et al., 2013). 
To date, large cohorts of Caucasian ALS cases have been assessed for the C9orf72 
HRE, however comparatively few studies of small cohorts of Asian cases have been 
conducted. We aimed to more accurately determine the frequency of the C9orf72 
HRE in a large cohort of Chinese sALS subjects, and investigate its relationship 
with SNP haplotypes and nearby CpG methylation. 
 
MATERIALS AND METHODS 
Participants 
Patients attending the ALS specialty clinic at the Department of Neurology of the 
Peking University Third Hospital, Beijing, China, from 2003-2013 were recruited. 
Patients in the case cohort were diagnosed with ALS according to El Escorial 
revised criteria (Brooks, et al., 2000) by a neurologist specializing in ALS. In the 
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present analysis, only sALS cases were included based on self-report and clinical 
interview. The cohort consisted of 65% males, while mean age of onset of sALS was 
49.7 ± 12.2 years. The proportion of patients with bulbar onset was 17%. The 
control samples were from individuals who attended the same hospital and Shanghai 
Changzheng Hospital, and who had no medical or family history of neurological 
disorders. All patients and control subjects were from mainland China and of 
Chinese origin. Control cohorts were age- and sex-matched neurologically healthy 
individuals. Table 1 describes the demographic characteristics of the cases and 
controls. All patients and controls provided written informed consent for the clinical 
and genetic studies during their visit to the neurologist. The Peking University Third 
Hospital and Changzheng Hospital ethics committees approved the collection of 
DNA samples from case and control subjects. 
Repeat-Primed PCR 
Genomic DNA from 1,092 patients with sALS and 1,062 controls subjects was 
extracted from blood using standard protocols. Two-step polymerase chain reaction 
(PCR) was performed to detect C9orf72 HRE as previously described (DeJesus-
Hernandez, et al., 2011). Briefly, fluorescent fragment-length analysis was 
performed with genotyping primers. The samples with a homozygous peak pattern 
were analyzed by fluorescent repeat-primed PCR to identify HREs. The HRE was 
defined as repeat number greater than 30 (Renton, et al., 2011) indicated by the 
typical “saw-tooth” pattern seen by repeat-primed PCR.  
Haplotype SNP Analysis, Principal-component Analysis and Validation 
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Genome-wide genotyping was performed using IlluminaHumanOmniZhongHua 
DNA analysis arrays (900,015 SNPs/individual) and manufacturer’s protocols. Bead 
intensity data was processed and normalized for each sample, and genotypes 
extracted in Genome Studio (Illumina). In order to predict haplotypes with greater 
accuracy a larger cohort of 3,115 control samples was used for haplotype analysis. 
939 cases and 2,850 controls survived after QC with 784,352 SNPs/individual. SNP 
genotypes from HRE carriers were validated by direct sequencing. The SNPs tested 
included 20 from the consensus risk founder haplotype in several ALS populations 
(K. Mok, et al., 2012) and three additional SNPs flanking the repeat (previously 
included by (Smith, et al., 2013)). Haplotype analysis of the 23 SNPs within and 
surrounding C9orf72 was performed by direct investigation and data imputation 
(using IMPUTE2)(Howie, et al., 2011), with the 1,000 Genomes Project reference 
panel, Phase I version 3 to determine whether the Chinese patients carried the 
founder haplotype associated with a risk for ALS. Haplotype reconstruction and 
frequency estimations were performed using PHASE (version 2.1.1, Chicago, IL) 
(Stephens, et al., 2001). Principal component analysis (PCA) was conducted by 
using the software package EIGENSTRAT(Price, et al., 2006). Detailed methods are 
provided in Tables S1and S3in the supplementary materials. 
DNA methylation analysis 
Genome-wide methylation levels in DNA extracted from blood of 461 sALS cases 
and 198 controls (a subset of those with genome-wide genotyping) were measured 
using the HumanMethylation450BeadChip (Illumina) following manufacturer’s 
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protocols. Bead intensity data was background-corrected and normalized using 
internal controls, and methylation beta-values extracted using the minfi package in R 
CRAN (http://cran.r-project.org/). Low quality samples and probes were removed. 
To assess the level of DNA methylation in the C9orf72region, beta-values for all 
eight probes annotated to the C9orf72 region (based on Illumina probe annotation) 
were extracted, which detected two predicted CpG islands (From UCSC database) 
closely flanking the GGGGCC repeat. 
 
RESULTS 
C9orf72 genotypes in Chinese ALS cases and controls 
The HRE was identified in three Chinese patients with sALS (Ch_MND_11134; 
Ch_MND_8446; Ch_MND_9059) of the 1,092 (0.3%) cases genotyped, and was not 
found in controls (p=0.25, Fisher’s exact test). The average repeat number in the 
1,089 ALS patients without the HRE was 3.79 ± 2.59 (range 2-25), while the repeat 
number in the 1,062 control subjects was 3.84± 2.60 (range 2-23). The repeat 
number distribution of the alleles is shown in (Figure 1). PCA showed minimal 
evidence for population stratification. The three patients carrying the HRE were not 
ethnic outliers, and are not closely related to one another (genomic relationship 
matrix elements<0.01)(Yang, et al., 2010). 
All three HRE carriers showed classic clinical manifestation of ALS with 
progressive respiratory dysfunction. Ch_MND_8446 had spinal-onset ALS 
characterized by right arm weakness beginning at age 58. He presented with 
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dysarthria and difficulty swallowing, and the patient died of ALS three years later. 
Ch_MND_9059 initially suffered from weakness in both hands at age 58 and died 
from respiratory failure within 15 months after the onset of symptoms. 
Ch_MND_11134 presented with weakness in the left leg at age 54. He presented 
with progressive respiratory dysfunction and received a tracheotomy three years 
later, but the patient died within six months after the tracheotomy. 
 
Haplotype analysis of the C9orf72 locus 
Genotypes were generated from 23 SNP loci located within 121 kilobases of 
C9orf72. In single marker analysis, no SNPs or haplotypes showed any significant 
association with ALS risk. The total set of consensus European risk alleles and risk 
allele A of rs2814707 was not found in the three HRE carriers (Table 2). Five alleles 
emphasized in defining the 20-SNP European founder risk haplotype (A of 
rs2814707, A of rs3849942, C of rs774359, G of rs2282241, and G of rs1982915) 
were not present in two of the three cases (Ch_MND_9059 and Ch_MND_11134). 
For the two SNPs flanking the repeat (rs2282441 and rs11789520), these two cases 
were homozygous for T and C alleles, while the European founder carries G and T 
alleles respectively. Thus for these two individuals their genotypes were inconsistent 
with the haplotype attributed to the European founder chromosome (Table 2, grey 
shading on genotypes). 
Analysis of the genotype data together with data from 1000 Genomes CHB subjects 
generated inferred haplotypes for the three HRE carriers (Table S2) that were robust 
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to different PHASE parameters (deviations from the stepwise mutation model or 
inclusion of the repeat genotypes,Table S3). The inferred haplotype solution 
allocates a shared 23-SNP haplotype harboring the HRE in Ch_MND_11134 and 
Ch_MND_8446; this haplotypes (excluding the HRE, 
TTGGAAACCCGTGTCACCAAAGT) has a frequency of 0.049 in cases and, 0.056 
in controls). With only three individuals identified with the C9orf72HRE we believe 
the statistically inferred haplotype should be interpreted with caution. To add insight 
we explored alternative haplotype solutions, for example all three HRE have 
genotypes that could be consistent with a shared 22-SNP haplotype. Such an 
alternative haplotype could be shared by Ch_MND_11134 and Ch_MND_9059, 
while the HRE is harboured on the European published haplotype for 
Ch_MND_8446. We calculated the frequencies of the haplotype possibilities in 
1000 Genomes and cases and controls (Table S2), and examined reported genotypes 
for other published studies for Chinese or Japanese cohorts (Table S4) but were 
unable to draw conclusions. 
The frequency of the Finnish 20-SNP haplotype was 1.8% in cases and 1.9% in 
controls (p=0.89). The C9orf72 repeat copy number in cases was significantly 
higher for the 29 Finnish 20-SNP haplotypes compared to all other haplotypes 
(Table S6); Fisher’s Exact test comparing the frequency of alleles less than 8 repeats 
vs alleles of8 or more repeats (3 vs1459 with fewer than 8, and 26 vs108 with 8 or 
morerepeats, p =0).The frequency of the haplotype shared by the two HRE carriers 
Ch_MND_11134 and Ch_MND_9059 (“Chinese haplotype”) has similar frequency 
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in cases and controls (4.9% vs 5.6%, p=0.26). However, as for the Finnish haplotype, 
alleles with 8 or more repeats were more common inthe80“Chinese haplotypes” 
found in cases (alleles with fewer than 8 repeats (62vs 1398) vs alleles with 8 or 
more repeats (14vs118) p = 4.6x10-3 or p=4.8x10-4 after excluding Finnish 
haplotypes). These results imply that the Chinese haplotype like the Finnish 
haplotype is associated with repeat length instability. 
CpG Methylation in the vicinity of C9orf72 
We next performed DNA methylation analysis of the three HRE carriers and 656 
non-carriers (458 sALS cases, 198 healthy controls). Three probes located within the 
CpG island immediately upstream of the repeat (cg14363787, cg23074747 and 
cg05990720; Figure 2,Table S5), showed increased CpG methylation for two HRE 
carriers (Ch_MND_11134, Ch_MND_9059); the two individuals whose SNP 
genotypes are inconsistent with the reported European risk haplotype) and no 
significant change in the third patient (Ch_MND_8446) (2/3 carriers, 0/656 non-
carriers).Ch_MND_11134 showed the greatest increase in methylation amongst all 
659 samples tested. All non-carriers showed low methylation levels at the four CpG 
sites closest to the repeat and in these individuals the correlation between 
methylation levels and repeat length was not significantly different from zero. A 
conservative estimate of the probability of the observed results occurring by chance 
is to consider the results of only cg14363787, cg23074747 for which 
Ch_MND_11134 and Ch_MND_9059 were ranked first and second out of all cases. 
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Such low probability (((3x8)/(461*460))2 = 1.2 x10-8) is consistent with a causal 
functional role for these expansion carriers. 
DISCUSSION 
This study confirms that C9orf72 repeat expansions are less prevalent in patients of 
Chinese compared to Caucasian ethnicity. The expansion was identified in 3/1,092 
cases compared to 0/1,062 controls. Given the low prevalence, this difference 
doesnot achieve statistical significance (Fisher’s exact test, p =0.25). The HRE has 
previously been identified in Caucasian control subjects with an observed frequency 
of 0-0.4% (Beck, et al., 2013,Galimberti, et al., 2014,Majounie, et al., 2012,Renton, 
et al., 2011), almost as small as the frequency found in our sALS cohort. We are 
unable to provide statistical or functional proof that the HREs detected in the 
Chinese cohort are the cause of ALS in the three identified cases, rather than the 
equivalent to HREs found in non-ALS cohorts of European ancestry. However, the 
HRE was not found in 1,062 Chinese controls in our study or Chinese healthy 
controls reported by others (Jiao, et al., 2014,Zou, et al., 2013). Increased 
methylation of the CpGisland upstream of the repeat supports that, at least for the 
two patients who do not have a diplotype consistent with the European haplotype, 
the HREs are full expansions rather than large alleles indistinguishable from full 
expansions by the limitations of repeat-primed PCR. It should be noted that full 
expansions could be definitively confirmed using Southern blot analysis (Beck et al, 
2013), however, asufficient quantity of DNA was unavailable for each of the three 
cases. Identification of further C9orf72 HRE carriers in China, and confirmation by 
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Southern blotting in the future will be necessary to strengthen our conclusions that 
the HRE may occurindependent from the Finnish founder. We note that the HRE 
testing and the methylation analysis of the samples occurred independently at two 
different locations (Beijing and Brisbane respectively). Similarly, the SNP 
genotyping was conducted in Beijing and the genome-wide SNP genotyping was 
conducted in Brisbane. This strategy of convenience also provides confidence that 
our results are protected from technical error. The chance of the methylation outliers 
occurring in the same samples as those with HRE by chance is unlikely (P<10-8) and 
we conclude that methylation is the result of GGGGCC expansion. 
 
The frequency of the C9orf72 HRE in several Caucasian ALS cohorts range from 
10.95%- 47% in fALS and 3.20%- 21.1% in sALS(Garcia-Redondo, et al., 
2013,Gijselinck, et al., 2012,Majounie, et al., 2012,Millecamps, et al., 2012,K.Y. 
Mok, et al., 2012,Ratti, et al., 2012,Sabatelli, et al., 2012). The reported frequencies 
in Asian samples have been lower (Ishiura, et al., 2012,Konno, et al., 2012,Majounie, 
et al., 2012,Ogaki, et al., 2012) but with a higher frequency reported in cases from 
Taiwan of Han Chinese ancestry (18.2% in fALS and 2.0% in sALS) (Tsai, et al., 
2012). In the present study, we report that the frequency of the C9orf72 HRE in 
Chinese sALS patients is 0.3%. To date, this is the largest cohort screened in non-
Caucasian ALS cases. Previous reports about C9orf72 HRE in different populations 
support the hypothesis that the pathogenic HRE arose from a single founder 
haplotype both in European and Asian populations (Ishiura, et al., 2012,Jiao, et al., 
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2014,Konno, et al., 2012,Majounie, et al., 2012,K.Y. Mok, et al., 2012,Ogaki, et al., 
2012,Tsai, et al., 2012) and for cases in Taiwan it was postulated that the HRE was 
introduced in the 17th century when Taiwan was under Dutch and Spanish colonial 
rule. The conjecture that Asian HREs arose on the same European founder seems 
inconsistent with the mutation occurring in a founder 1,500 years ago (Majounie, et 
al., 2012), since our study identified individuals with SNP alleles closely flanking 
the HRE that are not part of the reported haplotype. The A allele of rs2814707 has 
been used as a significant genetic association marker of chromosome 9p21 in the 
Flanders-Belgian cohort of patients with FTLD, FTLD-ALS, and ALS (odds ratio 
2.6, 95% CI 1.5-4.7; p=0.001) (Gijselinck, et al., 2012). However, this allele was not 
found in our cases carrying the C9orf72 HRE, corresponding with the absence of 
association between rs2814707 on 9p21 and sALS in Japanese or Chinese 
populations (Iida, et al., 2011). The A allele of rs3849942 has also been associated 
with an increased risk of ALS (Beck, et al., 2013), and this variant was not present 
in Ch_MND_9059 or Ch_MND_11134. Four additional SNP alleles present on the 
European founder haplotype were also not found in these two patients.  
Only one report has suggested that the HRE has occurred on multiple haplotypes in 
Europeans (Beck, et al., 2013) but others have concluded that the risk haplotype 
holds worldwide including in the Chinese and Japanese ALS populations (Pliner, et 
al., 2014). The information provided by Chinese samples we report here 
conclusively shows that in Chinese cases, ALS-associated C9orf72 repeats are found 
on different haplotypes to the European risk haplotypes. The mutation on the 
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European founder remains the most common known cause of ALS in Caucasian 
populations, but the possibility of rare, independent mutations should not be ruled 
out.  
Our exploration of the relationship between presence of the HRE and aberrant CpG 
methylation should be interpreted with caution given only 3 HRE carriers were 
identified. None-the-less, hypermethylation of CpGdinucleotides is an epigenetic 
modification that could lead to gene silencing or reduction of the amount of 
transcript produced. The previously reported methylation study on a larger cohort of 
Caucasian HRE carriers showed heterogeneity in the level of methylation (Xi, et al., 
2013). Consistent with this observation, only two of the three Chinese HRE carriers 
showed hyper-methylation at CpG sites assessed. In the Caucasian study, 
methylation of the CpGisland was not found in samples containing normal or 
intermediate sized alleles (up to 43 repeats). The presence of the HRE along with 
methylation of the upstream CpGisland suggests that the HREs, for at least two of 
the Chinese ALS patients are full repeat expansions rather than large alleles 
indistinguishable from full expansions by the limitations of repeat-primed PCR. 
Methylation status at these sites is of importance given the hypotheses of RNA 
toxicity of the transcribed repeat and/or toxicity of dipeptides translated from the 
transcribed repeat. Both could be influenced by the amount of HRE-containing 
transcript produced, which is influenced by methylation of the HRE and nearby CpG 
sites (Xi, et al., 2013)). 
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As well as reduced frequency of repeat expansions, the size distribution of normal 
alleles also differs between the Han Chinese cohort and that reported in Caucasians. 
Caucasian chromosomes contain a range of alleles with up to43 copies (Beck, et al., 
2013,Xi, et al., 2013) whereas in the Chinese samples alleles with more than 12 
repeats were rarely observed (Figure 1). For other diseases for which repeat 
expansion mutations are causal a lower frequency of larger, normal alleles in a 
population was related to a reduced incidence of repeat expansion associated 
disease(e.g. myotonic dystrophy (Zerylnick, et al., 1995)), implying that higher 
repeat lengths are associated with genomic instability. Germline mutation from a 
normal range or a pre-mutation range allele to a full expansion is yet to be observed 
for the C9orf72 repeat. However, a sporadic ALS case has recently been described 
with 90 copies of the CCGGG repeat in blood, but over 3000 copies in brain and 
spinal cord (Fratta, et al., 2014). This somatic instability suggests that alleles with 90 
copies of the repeat are possibly within the pre-mutation range for C9orf72 e.g. 
although perhaps not pathogenic as 90 copies, upon transmission (both germline and 
somatic) can give rise to a larger pathogenic expansion. Thus the rules for dynamic 
mutation appear to apply to the C9orf72 repeat where upon transmission, a dynamic 
mutation allele has a higher chance of mutation that its predecessor (Sutherland and 
Richards, 1995). Three HREs have been identified in our Han Chinese ALS patients, 
and at least two do not carry the reported European haplotype, which could imply 
that alleles of the C9orf72hexanucleotide repeat susceptible to dynamic mutation, 
independent of the European founder chromosome, do occur but are rare. The 
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European haplotype associated with pathological HRE does exist in the Chinese 
population, albeit at lower frequency (<2% in Chinese controls, compared to ~9% in 
European controls) and in our case sample the haplotype is highly associated with 
repeat length greater than 8 as in Europeans (90% of Finnish haplotypes vs7% of 
other haplotype, p=0, Table S6). Interestingly, the haplotype associated with two of 
the three Chinese HRE carrierswhich has frequency ~5% in both cases and controls 
is also associated with repeat alleles of 8 or more copies (20% vs 8% in other 
haplotypes, p=6.3 x10-4; Table S7). These results imply both the Finnish and 
Chinese haplotypes associated with HRE may confer instability of repeat length. 
Bulbar onset and cognitive impairment are more common in ALS patients with the 
C9orf72 HRE (Snowden, et al., 2013,Stewart, et al., 2012). The three Chinese 
patients harboring the C9orf72 expansion presented with spinal onset but no 
cognitive impairment. Although the age of onset has been reported to be younger in 
sALS patients with the HREs compared to those without expansions, our patients 
developed the symptoms at a relatively older age. Given that we report only three 
HRE carriers, it is not possible for us to make conclusions regarding the role of the 
HRE or CpG methylation in disease onset or progression in Chinese ALS. 
In conclusion, the present study demonstrates the low frequency of the C9orf72 
HRE in Chinese sALS patients from mainland China. HRE in Chinese sALS was 
associated with methylation of the upstream CpGisland in a pattern that appears 
similar to that in Caucasian ALS. The distinct alleles in SNPs flanking the HRE at 
~1kb in Chinese sALS patients compared to the European 20-SNP consensus risk 
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haplotype does not support the hypothesis that the C9orf72 expansion arose in a 
single founder about 100 generations ago (Pliner, et al., 2014). 
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LEGENDS TO FIGURES 
Figure 1. 
The frequency of alleles with different repeat copy numbers in sporadic ALS 
patients (n=1,092) and control subjects (n=1,062). 
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Figure 2. 
Boxplots of the methylation signal in cases and controls for theC9orf72probes 
andDNA methylation levels in C9orf72 gene region. 
The boxes show individuals with beta values between the 1st and 3rd quartiles, the 
black horizontal line shows the median methylation value in cases and controls, and 
outliers (methylation values more than 1·5 times inter-quartile range) are shown as 
black circles. The methylation level for each probe in the three individuals with 
repeat expansion is shown in red (together with sample ID). The distance of the CpG 
probe to the transcription start site (TSS) is given above each figure. Below the box 
plots is a physical map of the HRE interval and positions of CpG islands. The 
zoomed in interval shows position of CpGs with increased methylation associated 
with the HRE. One asterisk indicates probes with increased methylation in 
Ch_MND_11134 only, two asterisks indicates probes with increased methylation in 
both Ch_MND_11134 and Ch_MND_9059. The positions of CpGs tested by Xi et 
al, are shown below the scale bar using the numbering from their report (Xi, et al., 
2013). The hashed lines connecting the probes assessed in this report and CpGs 
below the scale, indicated CpGs common to both studies. The numbering of the 
chromosomal location above the scale bar are from the UCSC Genome Browser, 
build GRCh37/hg19. In our study, at the four probes closest to the TSS (from 
cg05990720 to cg23074747), two of all three cases(Ch_MND_11134, 
Ch_MND_9059)have increased levels of methylation. All656 non-carriers showed 
very low methylation levels at the 4 CpG sites closest to upstream of the 
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repeat.Despite the very small sample size, our results showed clear and similar 
differences in methylation levels at CpG sites near the HRE in carriers. 
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TABLES  
Table 1．Demographics of the case and control cohorts analyzed for the 
frequency of the HRE in C9orf72. 
 
 
Sporadic ALS patientsa Controls for mutation 
screeningb 
Controls for haplotype 
analysisd 
Total  1,092 1,062 2,850 
  Male  697 (65.20%) 561 (54.05%) 1,213(42.57%) 
  Female  372 (34.80%) 477 (45.95%) 1,637(57.43%) 
Age at onset    
  Mean ±SD 49.70 ± 12.22  50.25 ± 14.90c - 
Site of onset    
  Bulbar 131 (17.08%) - - 
  Spinal  636 (82.92%) - - 
 
a
 Data not available for the gender of 23 patients, age of onset for 311 patients, site 
of onset for 325 patients. 
bData not available for the gender for 24 control subjects, age at enrollment for 24 
control subjects.  
c
 Age at enrollment for control cohort. 
dHealthy controls survived after quality control. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT He 
 
 
29
 
Table 2．The genotyping data of the single nucleotide polymorphisms (SNPs) 
surrounding C9orf72. 
  
  
  
Markera 
  
Position 
(bp) 
  
Reference/ 
Alternative 
Allele 
 
Risk 
Haplotypea 
Frequency of 
Risk Alleleb 
Genotypes of the 3 HRE 
individualsc: IDs 
ASN EUR 11134 8446 9059 
1 rs1822723 27478052 C/T C 0.63 0.73 T/T C/T C/C 
2 rs4879515 27482235 C/T T 0.67 0.46 T/T T/T T/T 
3 rs868856 27489251 T/C T 0.32 0.28 T/C T/C T/T 
4 rs7046653 27490967 A/G A 0.32 0.28 A/G A/G A/A 
5 rs1977661 27502986 C/A C 0.69 0.89 C/A C/A C/C 
6 rs903603 27529316 C/T C 0.38 0.49 C/T C/T C/T 
7 rs10812610 27533984 C/A C 0.39 0.48 C/A C/A C/A 
8 rs2814707 27536397 G/A A 0.06 0.25 G/G G/G G/G 
9 rs3849942 27543281 A/G A 0.08 0.25 G/G A/G G/G 
10 rs700791 27545960 C/A A 0.08  0.25 C/C A/C C/C 
11 rs10122902 27556780 G/A G 0.69 0.84 G/A G/G G/A 
12 rs10757665 27557919 T/C T 0.89 0.75 T/T T/T T/T 
13 rs1565948 27559733 G/A G 0.57 0.53 G/A G/G G/A 
14 rs774359 27561049 T/C C 0.08 0.27 T/T C/T T/T 
15 rs2453554 27561800 C/T T 0.08  0.26 C/C T/C C/C 
16 rs2282241 27572255 G/T G 0.32 0.57 T/T G/T T/T 
  C9orf72HR 27573483 30+ 30+     30+/2 30+/2 30+/2 
17 rs11789520 27574515 C/T T  0.08  0.26 C/C C/T C/C 
18 rs1948522 27575785 C/T C 0.88 0.82 C/C C/C C/C 
19 rs1982915 27579560 A/G G 0.22 0.47 A/A G/A A/A 
20 rs2453556 27586162 A/G G 0.46 0.37 G/A G/A G/A 
21 rs702231 27588731 C/A A 0.65 0.78 A/C A/C A/A 
22 rs696826 27589657 A/G G 0.99 0.86 G/G G/G G/G 
23 rs2477518 27599746 T/C T 0.85 0.75 T/T T/T C/T 
 
a: Of the 23 SNPs genotyped 20 contributed to the risk haplotype of (Laaksovirta, et 
al., 2010). The SNPs shaded in grey were included in some subsequent studies e.g. 
(Smith, et al., 2013). 
b. The frequency of the haplotype risk alleles derived from the 1,000 Genomes 
database (www.1000genomes.org/); EUR = frequency estimated from 379 
individuals from 1000G populations labeled CEU, FIN, GER, IBS and TSI;ASN = 
frequency estimated from 286 individuals from 1000G populations labeled CHB. 
c. Genotypes of the Chinese individuals that are incompatible with the European risk 
haplotype are shaded grey. 
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cg13716323
cg13615109
27,610,000 27,605,000 27,600,000 27,595,000 27,590,00027,615,000
NM_001256054
NM_145005
27,574,000 27,573,900 27,573,800
cg14363787
27,573,985
cg11613875
27,573,888
cg23074747
27,573,816
1                  2                        3   4     5         6 7     8 9      10             11 13 15              16 17 18       19 21 23     24       25       26     
12 14 20 22
27,574,200 27,574,100
CpG: 20
* **
* *
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Highlights 
• We have examined the C9orf72 gene in the largest cohort of sporadic ALS cases from a 
non-Caucasian population. 
• We conducted a series of comprehensive genetic tests including C9orf72 hexanucleotide 
repeat expansion screening, haplotype analysis and methylation analysis of CpG sites 
surrounding C9orf72. 
• When compared with Caucasian populations there is a low frequency of the repeat 
expansion mutation. The Chinese cases we describe are the first expansions that 
conclusively do not occur on the same founder haplotype as European cases. 
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Table S1 Primers and protocols for repeat PCR 
A. Primer sequences for the repeat-primed PCR(DeJesus-Hernandez, et al., 2011) 
Step Primer name Sequence  
Fragment length PCR  Chr9:27563580F FAM-CAAGGAGGGAAACAACCGCAGCC 
Chr9:27563465R GCAGGCACCGCAACCGCAG 
Repeat-primed PCR 
MRX-F FAM-TGTAAAACGACGGCCAGTCAAGGAGGGAAACAACCGCAGCC 
MRX-M13R CAGGAAACAGCTATGACC 
MRX-R1 CAGGAAACAGCTATGACCGGGCCCGCCCCGACCACGCCCCGGCCCCGGCCCCGG 
 
B. PCR cycling conditions 
Step  Temperature  Time  Repeat  
Fragment length PCR 
95° 5 min  
95° 1 min 
30 cycles 64° 1 min 
72° 1 min 
72° 60 min  
Repeat-primed PCR 
95° 5 min  
95° 1 min 
30 cycles 62° 1 min 
72° 1 min 
72° 60 min  
 
C. Primers used to amplify the set of 23 SNPs within and surrounding the C9orf72 gene. 
rs number  Position  Forward primer Reverse primer  
rs1822723* 27478052 TGCAAGGTAAGATGCTGGAA TTGCTTCTTCCCTGGTTCTG 
rs4879515* 27482235 TGAACGAAAAGCACGGTAAA AGTAAGCCCCCAAAGGAGAC 
rs868856* 27489251 GGTCTGACAGAAGCCTTTGC TGGCTCCCACGGTAGTTTTA 
rs7046653* 27490967 CATCGATGCTGTAGGCACAA TCTCATCGTTCCGAAGAAAT 
rs1977661* 27502986 TCACAGGAAAGTAGGCAGGAA TCCTCCAGTCTAGTCACCCCTA 
rs903603* 27529316 CTGCTCGCTCCCGATCTC CCCAGGCGCACTTTTGTA 
rs10812610* 27533984 GGTTTCTATCCAGTGTCCCAGA GCATGTTTGGGTCTCCATCT 
rs2814707* 27536397 GCCTCCTGTAATTGCTCACC TCCCCTTTTCACCTCTCTCA 
rs3849942* 27543281 TCAGAGTGCTGTGGTACGATT GCGCTCCACAGATGGATACT 
rs700791 27545960 ACAGCAGGGATTCACACTCG ACACTTTCATCTGCAAAGCTAGG 
rs10122902* 27556780 TGAAGTGGCTCTCCAGAAGG TTTGCACACACTCATGAATAGC 
rs10757665* 27557919 TTGAAAATGCACAAAAGCCTAA GGATTTAAGCAATTCCTATGTATGTGT 
rs1565948* 27559733 GGTTTGCTGAAATTGAAAGATACA TCATCTTGATTTCATTGTCTTCG 
rs774359* 27561049 GGCACTCAACAAATACTGGCTA CTTTTTCCATCCAGCAGTGG 
rs2453554 27561800 AGCAAGGGGCCATGATTTCT GTGGGAGGATCCCAGCTCTT 
rs2282241* 27572255 TTCTCAGACTTTGGGAAACTTTTA TGCCAACATAGCCAAACAAA 
C9orf72 repeat 
expansion 
27573483 
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rs11789520 27574515 GCGTCATCTTTTACGTGGGC GAACAGTAGGAAAAGGGTCTGT 
rs1948522* 27575785 CACCCCATAATCCACTCACC CCTTTCGGAATGGCAGTATC 
rs1982915* 27579560 GGCCAGTTTCATGCAATTCT TGTTTCAGGGTTGATATCACAAA 
rs2453556* 27586162 ATCATCCACTCCCCTCCTCT AACCAAGCAGCCATGAAAAG 
rs702231* 27588731 AACCATCTGTCTTCCTTCCATGTC AGGCAGTGTTTACTCGCCAC 
rs696826* 27589657 TTGCTGGAGTGTTTGCAGAG ATGAACCCAGCTGTCTCACC 
rs2477518* 27599746 CGTTTTGGGAAATCGCTTAG CAGGTGAAACCCATTTGTCA 
* from the 20 SNP consensus risk founder haplotype. 
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Table S2: Diplotypes and inferred haplotypes from PHASE analysis in Chinese ALS.  
 Markera Position 
(bp) 
European 
23-SNP 
Risk 
Haplotype 
Genotypes of the HRE carriersb PHASE inferred haplotypes Finnish 20-
SNP risk 
haplotypec 
23-SNP 
haplotype 
shared by 
2 HRE 
carriersd 
Haplotype 
shared by 
3 HRE 
carriers 
Haplotype 
shared by 
European and 
3 HRE carriers 11134 8446 9059 11134 8446 9059 
1 rs1822723 27478052 C T/T C/T C/C T T T C C C C T     
2 rs4879515 27482235 T T/T T/T T/T T T T T T T T T T T 
3 rs868856 27489251 T T/C T/C T/T C T C T T T T C     
4 rs7046653 27490967 A A/G A/G A/A G A G A A A A G     
5 rs1977661 27502986 C C/A C/A C/C A C A C C C C A     
6 rs903603 27529316 C C/T C/T C/T T C T C C T C T     
7 rs10812610 27533984 C C/A C/A C/A A C A C C A C A     
8 rs2814707 27536397 A G/G G/G G/G G G G G G G A G G   
9 rs3849942 27543281 A G/G A/G G/G G G G A G G A G G   
10 rs700791 27545960 A C/C A/C C/C C C C A C C  C C   
11 rs10122902 27556780 G G/A G/G G/A G A G G A G G G     
12 rs10757665 27557919 T T/T T/T T/T T T T T T T T T T T 
13 rs1565948 27559733 G G/A G/G G/A G A G G A G G G     
14 rs774359 27561049 C T/T C/T T/T T T T C T T C T T   
15 rs2453554 27561800 T C/C T/C C/C C C C T C C  C C   
16 rs2282241 27572255 G T/T G/T T/T T T T G T T G T T   
 C9orf72 HR 27573483 30+ 30+/2 30+/2 30+/2 30+ 2 30+ 2 30+ 2       
17 rs11789520 27574515 T C/C C/T C/C C C C T C C  C C   
18 rs1948522 27575785 C C/C C/C C/C C C C C C C C C C C 
19 rs1982915 27579560 G A/A G/A A/A A A A G A A G A A   
20 rs2453556 27586162 G G/A G/A G/A A G A G A G G A A   
21 rs702231 27588731 A A/C A/C A/A A C A C A A A A A A 
22 rs696826 27589657 G G/G G/G G/G G G G G G G G G G G 
23 rs2477518 27599746 T T/T T/T C/T T T T T T C T T T T 
 Cases (n=939) 33 89 374 470 
Controls (n=2,850) 105 310 1,174 1,469 
Haplotype Frequency in cases 0·018 0·049 0·23 0·30 
Haplotype Frequency in controls 0·019 0·056 0·23 0·30 
p value (χ2-test) 0·89 0·26 0·50 0·47 
1000G Phase 1 v3 (EUR: n=379) 68 31 49 182 
1000G Phase 1 v3 (ASN; n=286) 17 21 131 192 
Haplotype Frequency in EUR 0.09 0.04 0.07 0.24 
Haplotype Frequency in ASN 0.03 0.04 0.23 0.34 
p value difference (χ2-test) 3.80E-10 0.58 0 5.71E-08 
 
a: The 20 from the risk haplotype (Laaksovirta, et al., 2010) and 3 additional SNPs (shaded) use by others e.g. (Smith, et al., 2013). 
b: Genotypes of the Chinese HRE carriers that are incompatible with the European risk haplotype are shaded in grey.  
c: The 20- SNP risk haplotype associated with the C9orf72 gene and shared by most of the patients with ALS and FTD carrying C9orf72 expanded repeats in populations 
from Finland (Mok et al. 2012). 
d. PHASE was used to identify a 23-SNP haplotype shared between CH_MND_11134 and CH_MND_8447. 
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Chinese Han samples  
 
A. The Output with short burn-in (default; iteration: 100; thinning interval: 1; burn-in: 100) 
Ch_MND_11134  TTGGAAACCCGTGTCA 30 CCAAAGT   TTAACGCCCCATATCA 2 CCAGCGT  
Ch_MND_8446  TTGGAAACCCGTGTCA 30 CCAAAGT   CTAACGCCTAGTGCTC 2 TCGGCGT  
Ch_MND_9059  CTAACGCCCCATATCA 30 CCAAAGT   CTAACAACCCGTGTCA 2 CCAGAGC  
 
B. The Output with long burn-in (iteration: 100; thinning interval: 1; burn-in: 500) 
Ch_MND_11134  TTGGAAACCCGTGTCA 30 CCAAAGT   TTAACGCCCCATATCA 2 CCAGCGT  
Ch_MND_8446  TTGGAAACCCGTGTCA 30 CCAAAGT   CTAACGCCTAGTGCTC 2 TCGGCGT  
Ch_MND_9059  CTAACGCCCCATATCA 30 CCAAAGT   CTAACAACCCGTGTCA 2 CCAGAGC  
 
C. The output without microsatellite loci (iteration: 100; thinning interval: 1; burn-in: 100) 
Ch_MND_11134  TTGGAAACCCGTGTCA CCAAAGT   TTAACGCCCCATATCA CCAGCGT  
Ch_MND_8446  TTGGAAACCCGTGTCA CCAA(C)GT  CTAACGCCTAGTGCTC TCGG(A)GT  
Ch_MND_9059  CTAACGCCCCATATCA CCA(G)AG(C)   CTAACAACCCGTGTCA CCA(A)AG(T)  
Different parameters in the analyses were used to check for the consistency. The haplotype with the posterior 
probability >0.90 was accepted. Brackets: The alleles with probability <0.90. 
 
D. The output with long burn in with varying delta(Stephens, et al., 2001). 
Using PHASE analysis for microsatellite loci where the stepwise model is a good assumption, using that model (Delta = 
0, default) would provide more power to reconstruct haplotypes than other models (Delta > 0). However, using a small 
value for (Delta = 0.05 – 0.1) provides greater robustness to occasional deviations from the stepwise model(Stephens, et 
al., 2001). Using small values of delta (Delta = 0.05-0.25) yielded the same haplotypes. This result showed that the 
inferred haplotypes are quite robust to the occasional deviations from the stepwise mutation model. 
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Table S4  Reported genotypes of ALS cases carrying the HRE from Asia  
   Japan(Konno, et al., 2012,Ogaki, et al., 
2012) 
Taiwan(Tsai, et al., 2012) China(Jiao, et al., 2014) 
Marker European 
Haplotype 
ChMND 
Haplotype 
fALS 1  fALS 2  Family A  Family B  fALS/FTD A 
Phased  
fALS/FTD B 
Unphased 
fALS/FTD C 
Phased 
fALS D 
Unphased 
fALS/FTD FTD 
rs1822723* C  C/T C/T C C - - - - C C 
rs4879515* T T T/C T T T - - - - C/T T 
rs868856* T  T/C T/C T T - - - - C/T T 
rs7046653* A  A A/G A A A G/A A A G/A A 
rs1977661 * C  C C/A C C - - - - C C 
rs903603* C  C/T C/T C C/T C T/C C C C C 
rs10812610* C  C/A C/A C C/A - - - - C/A C 
rs2814707* A G A/G G A A/G G G/A A G/A G/A G 
rs3849942* A G A/G A/G A A/G A G/A A G/A G/A G/A 
rs700791 A C - - - - - - - - - - 
rs10122902* G  G G G G - - - - G G/A 
rs10757665* T T T/C T T T - - - - T T/T 
rs1565948* G  G/A G G G - - - - G G/A 
rs774359* C T C/T C/T C C/T C T/C C T/C C/T C/T 
rs2453554 T C - - - - - - - - - - 
rs2282241* G T G G/T G G/T - - - - G/T G/T 
C9orf72 repeat 
expansion 
            
rs11789520 T C - - - - - - - - - - 
rs1948522* C C C C C C - - - - C C 
rs1982915* G A G/A G/A G G/A G A/G G A/G G/A G/A 
rs2453556* G A G/A G/A G G/A G A/G G A/G G/A G/A 
rs702231* A A A A/C A A C C/A A A A/C A 
rs696826* G G G G G G - - - - G/C G 
rs2477518* T T T T T T - - - - C/T T 
 
The table includes ALS cases carrying a C9orf72 HRE and reported genotypes for SNPs in the region. ChMND haplotype is the haplotype from Table 
S3 that is shared by all 3 HRE carriers. SNPs that were homozygous in reported HRE carriers are recorded as a single allele. If phase was determined 
only the alleles from the haplotype associated with the HRE are shown.  Both alleles are shown for heterozygous SNPs where phase was not 
determined. The blue and grey shading indicate SNPs that distinguish the European haplotype from that found in our ALS cases from China (1 and 3), 
green shading indicates an allele not present on either haplotype, and “–“ indicates SNPs for which no genotypes were published.  
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ID Position 
TSS 
Position 
Distance 
to TSS 
Mean Beta 
value (Non-
carriers) 
Ch_MND_11134 
Beta value 
Ch_MND_8446 
Beta value 
Ch_MND_9059 
Beta value 
cg13958452 27571483 27573841 1997 0.93 0.92 0.89 0.98 
cg05990720 27573649 27573841 192 0.04 0.10 0.04 0.05 
cg23074747 27573816 27573841 25 0.03 0.28 0.03 0.06 
cg11613875 27573888 27573841 -47 0.01 0.07 0.00 0.02 
cg14363787 27573985 27573841 -144 0.05 0.27 0.06 0.10 
cg14634447 27576471 27573841 -2630 0.85 0.83 0.82 0.85 
cg13615109 27610825 27573841 -36984 0.62 0.56 0.63 0.66 
cg13716323 27610876 27573841 -37035 0.95 0.95 0.95 0.94 
TSS: transcription start site 
 
Table S6. The distribution of HRE repeat sizes of Finnish 20-SNP haplotype vs other haplotypes in 
cases. Fisher’s Exact test comparing the frequency of the repeat allele < 8 vs alleles of length 8 or 
greater (3 vs 1459 with fewer than 8 repeat alleles, and 26 vs 108 with 8 or more repeat allele, p = 
0). The threshold of 8 was selected based on the repeat lengths associated with the Finnish 
haplotype in Europeans (Beck et al, 2013). 
Repeat 
Size 
Finnish 
Haplotype % 
Other 
Haplotypes % 
All 
Haplotypes 
2 0 0.0 1016 64.8 1016 
3 0 0.0 12 0.8 12 
4 0 0.0 9 0.6 9 
5 0 0.0 11 0.7 11 
6 2 6.9 182 11.6 184 
7 1 3.4 229 14.6 230 
8 21 72.4 70 4.5 91 
9 2 6.9 11 0.7 13 
10 1 3.4 7 0.4 8 
11 1 3.4 5 0.3 6 
12 1 3.4 3 0.2 4 
13 0 0.0 6 0.4 6 
14 0 0.0 2 0.1 2 
18 0 0.0 1 0.1 1 
30 0 0.0 3 0.2 3 
29 100 1567 100 1596 
We could not provide the similar comparisons in controls because the control samples with repeat 
size information were not genotyped for the 23 flanking SNPs. 
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between 2 Chinese cases with HRE. Fisher’s Exact test comparing the frequency of the repeat allele 
< 8 vs alleles of length 8 or greater alleles (excluding the two HRE carriers, 62 vs 1398 with fewer 
than 8 repeat alleles, and 14 vs 118 with 8 or more repeat allele, p = 4.6 x 10-3 or  p=4.8x10-4 after 
excluding the Finnish haplotype carriers). The threshold of 8 was selected based on the repeat 
lengths associated with the Finnish haplotype in Europeans (Beck et al, 2013). 
 
Repeat 
Size 
Chinese 
Haplotype % 
Other 
Haplotypes % All Cases 
2 41 51.3 975 64.3 1016 
3 2 2.5 10 0.7 12 
4 0 0.0 9 0.6 9 
5 1 1.3 10 0.7 11 
6 9 11.3 175 11.5 184 
7 11 13.8 219 14.4 230 
8 8 10.0 83 5.5 91 
9 1 1.3 12 0.8 13 
10 0 0.0 8 0.5 8 
11 1 1.3 5 0.3 6 
12 2 2.5 2 0.1 4 
13 2 2.5 4 0.3 6 
14 0 0.0 2 0.1 2 
18 0 0.0 1 0.1 1 
30 2 2.5 1 0.1 3 
80 100 1516 100 1596 
We could not provide the similar comparisons in controls because the control samples with repeat 
size information were not genotyped for the 23 flanking SNPs. 
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